MURA

Mural Oncology plc Ordinary Shares

Healthcare — PHARMACEUTICAL PREPARATIONS

Valhalla Score —

—

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

📊 Key Statistics

Market Cap—

P/E Ratio—

EPS (TTM)—

EPS YoY—

Revenue YoY—

Float—

Short Float %—

Inst. Ownership—

Sector RS—

📈 Fundamentals

ROE—

ROIC—

ROA—

Current Ratio—

Debt/Equity—

Gross Margin—

Net Margin—

Dividend Yield—

Next Earnings—

⚡ Options Summary

Call OI—

Put OI—

P/C Ratio (OI)—

Gamma Environment—

Max Pain—

Call Wall—

Put Wall—

🎯 Analyst Estimates

Consensus Target—

High Target—

Low Target—

Analysts—

Upside/Downside—

📋 Quarterly Financials

Period	Revenue	Rev YoY	EPS	EPS YoY	Gross Margin

Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

Type	Strike	Exp	Size	Premium	Time

Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

Type	Price	Size	Value	Venue	Time

Start Free Trial Full insider & congressional trade history

👤 Insider Trades

Name	Type	Shares	Price	Date

Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

Institution	Shares	Value	% of Class